{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T17:49:25Z","timestamp":1773596965703,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,15]]},"DOI":"10.7759\/cureus.105269","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T17:28:31Z","timestamp":1773595711000},"source":"Crossref","is-referenced-by-count":0,"title":["Systematic Review Evaluating the Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use on the Postoperative Outcomes of Patients Undergoing Arthroplasty Procedures"],"prefix":"10.7759","author":[{"given":"Hannah","family":"Tabor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenu","family":"Ediripolage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimra","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irrum","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarkhell","family":"Radha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organisation. Obesity and Overweight Fact Sheet. (2025). Accessed. August 27, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-006351","article-title":"Economic impacts of overweight and obesity: current and future estimates for eight countries","volume":"6","author":"Okunogbe A","year":"2021","unstructured":"Okunogbe A, Nugent R, Spencer G, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Glob Health. 2021, 6:e006351. 10.1136\/bmjgh-2021-006351","journal-title":"BMJ Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults","volume":"390","year":"2017","unstructured":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016. a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults. Lancet. 2017, 390:2627-42. 10.1016\/S0140-6736(17)32129-3","journal-title":"Lancet"},{"key":"ref4","unstructured":"Obesity statistics. (2025). Accessed. August 27, 2025: https:\/\/commonslibrary.parliament.uk\/research-briefings\/sn03336\/."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2016.04.006","article-title":"Obesity and osteoarthritis","volume":"89","author":"Kulkarni K","year":"2016","unstructured":"Kulkarni K, Karssiens T, Kumar V, Pandit H. Obesity and osteoarthritis. Maturitas. 2016, 89:22-8. 10.1016\/j.maturitas.2016.04.006","journal-title":"Maturitas"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.16.00093","article-title":"Effect of body mass index on reoperation and complications after total knee arthroplasty","volume":"98","author":"Wagner ER","year":"2016","unstructured":"Wagner ER, Kamath AF, Fruth K, Harmsen WS, Berry DJ. Effect of body mass index on reoperation and complications after total knee arthroplasty. J Bone Joint Surg Am. 2016, 98:2052-60. 10.2106\/JBJS.16.00093","journal-title":"J Bone Joint Surg Am"},{"key":"ref7","unstructured":"Early screening, triaging, risk assessment and health optimisation in perioperative pathways. guide for providers and integrated care boards. (2025). Accessed: August 27, 2025: https:\/\/www.england.nhs.uk\/long-read\/earlier-screening-risk-assessment-and-health-optimisation-in-perioperative-pathw...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13741-024-00460-1","article-title":"Health optimisation for patients with obesity before elective orthopaedic surgery: a qualitative study of professionals' views on restrictive approaches and future practice","volume":"13","author":"McLaughlin J","year":"2024","unstructured":"McLaughlin J, Kipping R, McLeod H, Judge A, Owen-Smith A. Health optimisation for patients with obesity before elective orthopaedic surgery: a qualitative study of professionals' views on restrictive approaches and future practice. Perioper Med (Lond). 2024, 13:104. 10.1186\/s13741-024-00460-1","journal-title":"Perioper Med (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard J","year":"2021","unstructured":"Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021, 38:2821-39. 10.1007\/s12325-021-01710-0","journal-title":"Adv Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer X","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al.. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015, 373:11-22. 10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"ref13","unstructured":"GLP-1 medicines for weight loss and diabetes. what you need to know. (2026). Accessed: August 27, 2025: https:\/\/www.gov.uk\/government\/publications\/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know\/glp-1-m...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04528-7","article-title":"Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain","volume":"24","author":"Jackson SE","year":"2026","unstructured":"Jackson SE, Brown J, Llewellyn C, Mytton O, Shahab L. Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. BMC Med. 2026, 24:1. 10.1186\/s12916-025-04528-7","journal-title":"BMC Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.artd.2025.101667","article-title":"Effects of malnutrition on perioperative outcomes of total hip arthroplasty: a systematic review and meta-analysis","volume":"33","author":"Aziz A","year":"2025","unstructured":"Aziz A, Bluhm JB, Williamson TK, Atkison C, Eck A, Moore C, Buttacavoli FA. Effects of malnutrition on perioperative outcomes of total hip arthroplasty: a systematic review and meta-analysis. Arthroplast Today. 2025, 33:101667. 10.1016\/j.artd.2025.101667","journal-title":"Arthroplast Today"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2019.05.060","article-title":"The role of malnutrition in ninety-day outcomes after total joint arthroplasty","volume":"34","author":"Black CS","year":"2019","unstructured":"Black CS, Goltz DE, Ryan SP, Fletcher AN, Wellman SS, Bolognesi MP, Seyler TM. The role of malnutrition in ninety-day outcomes after total joint arthroplasty. J Arthroplasty. 2019, 34:2594-600. 10.1016\/j.arth.2019.05.060","journal-title":"J Arthroplasty"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1530\/EOR-23-0192","article-title":"Malnutrition in total joint arthroplasty: what should the orthopaedic surgeon consider?","volume":"9","author":"Almeida PR","year":"2024","unstructured":"Almeida PR, Mokete L, Sikhauli N, Mota A, Ndindwa B, Pietrzak JR. Malnutrition in total joint arthroplasty: what should the orthopaedic surgeon consider?. EFORT Open Rev. 2024, 9:615-24. 10.1530\/EOR-23-0192","journal-title":"EFORT Open Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2021.02.061","article-title":"Failure to optimize before total knee arthroplasty: which modifiable risk factor is the most dangerous?","volume":"36","author":"Johnson NR","year":"2021","unstructured":"Johnson NR, Statz JM, Odum SM, Otero JE. Failure to optimize before total knee arthroplasty: which modifiable risk factor is the most dangerous?. J Arthroplasty. 2021, 36:2452-7. 10.1016\/j.arth.2021.02.061","journal-title":"J Arthroplasty"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOSGlobal-D-24-00148","article-title":"Glucagon-like peptide-1 agonists in total hip arthroplasty: complications, readmissions, and patient-reported outcomes","volume":"8","author":"Magaldi RJ","year":"2024","unstructured":"Magaldi RJ, Strecker SE, Witmer D. Glucagon-like peptide-1 agonists in total hip arthroplasty: complications, readmissions, and patient-reported outcomes. J Am Acad Orthop Surg Glob Res Rev. 2024, 8:e24.00148. 10.5435\/JAAOSGlobal-D-24-00148","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2023.05.071","article-title":"Does semaglutide use decrease complications and costs following total knee arthroplasty?","volume":"38","author":"Magruder ML","year":"2023","unstructured":"Magruder ML, Yao VJ, Rodriguez AN, Ng MK, Sasson V, Erez O. Does semaglutide use decrease complications and costs following total knee arthroplasty?. J Arthroplasty. 2023, 38:2311-5.e1. 10.1016\/j.arth.2023.05.071","journal-title":"J Arthroplasty"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2025.02.042","article-title":"Trends, demographics, and outcomes for glucagon-like peptide-1 receptor agonist use in total knee arthroplasty: an 11-year perspective","volume":"40","author":"Katzman JL","year":"2025","unstructured":"Katzman JL, Haider MA, Cardillo C, Rozell JC, Schwarzkopf R, Lajam CM. Trends, demographics, and outcomes for glucagon-like peptide-1 receptor agonist use in total knee arthroplasty: an 11-year perspective. J Arthroplasty. 2025, 40:S176-83. 10.1016\/j.arth.2025.02.042","journal-title":"J Arthroplasty"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.05.079","article-title":"Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty","volume":"39","author":"Buddhiraju A","year":"2024","unstructured":"Buddhiraju A, Kagabo W, Khanuja HS, Oni JK, Nikkel LE, Hegde V. Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty. J Arthroplasty. 2024, 39:2911-5.e1. 10.1016\/j.arth.2024.05.079","journal-title":"J Arthroplasty"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-24-01284","article-title":"The effects of glucagon-like peptide-1 agonist therapy on risk of infection, fracture, and early revision in primary total joint arthroplasty","volume":"33","author":"Levidy MF","year":"2025","unstructured":"Levidy MF, Vatsia S, Gohel N, Rowe N, Kirchner GJ, Demedal S, Mason M. The effects of glucagon-like peptide-1 agonist therapy on risk of infection, fracture, and early revision in primary total joint arthroplasty. J Am Acad Orthop Surg. 2025, 33:1213-8. 10.5435\/JAAOS-D-24-01284","journal-title":"J Am Acad Orthop Surg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.10.099","article-title":"Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total hip arthroplasty in patients who have type 2 diabetes","volume":"40","author":"Heo KY","year":"2025","unstructured":"Heo KY, Goel RK, Woltemath A, et al.. Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total hip arthroplasty in patients who have type 2 diabetes. J Arthroplasty. 2025, 40:1413-8.e1. 10.1016\/j.arth.2024.10.099","journal-title":"J Arthroplasty"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.12.008","article-title":"Utilization of glucagon-like peptide-1 receptor agonist at the time of total hip arthroplasty for patients who have morbid obesity","volume":"40","author":"Kim BI","year":"2025","unstructured":"Kim BI, Khilnani TK, LaValva SM, Goodman SM, Della Valle AG, Lee GC. Utilization of glucagon-like peptide-1 receptor agonist at the time of total hip arthroplasty for patients who have morbid obesity. J Arthroplasty. 2025, 40:S259-64.e1. 10.1016\/j.arth.2024.12.008","journal-title":"J Arthroplasty"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2023.12.023","article-title":"Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions","volume":"39","author":"Magruder ML","year":"2024","unstructured":"Magruder ML, Miskiewicz MJ, Rodriguez AN, Mont MA. Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions. J Arthroplasty. 2024, 39:716-20. 10.1016\/j.arth.2023.12.023","journal-title":"J Arthroplasty"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2025.03.012","article-title":"GLP-1 agonists for weight loss: do they increase complications in non-diabetic patients undergoing primary total hip arthroplasty?","volume":"40","author":"Verhey JT","year":"2025","unstructured":"Verhey JT, Austin RP, Tarabichi S, et al.. GLP-1 agonists for weight loss: do they increase complications in non-diabetic patients undergoing primary total hip arthroplasty?. J Arthroplasty. 2025, 40:S101-7. 10.1016\/j.arth.2025.03.012","journal-title":"J Arthroplasty"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.artd.2024.101506","article-title":"Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total knee arthroplasty in patients with type-2 diabetes","volume":"30","author":"Heo KY","year":"2024","unstructured":"Heo KY, Goel RK, Fuqua A, et al.. Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total knee arthroplasty in patients with type-2 diabetes. Arthroplast Today. 2024, 30:101506. 10.1016\/j.artd.2024.101506","journal-title":"Arthroplast Today"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.24.00468","article-title":"Glucagon-like peptide-1 receptor agonists decrease medical and surgical complications in morbidly obese patients undergoing primary TKA","volume":"107","author":"Kim BI","year":"2025","unstructured":"Kim BI, LaValva SM, Parks ML, Sculco PK, Della Valle AG, Lee GC. Glucagon-like peptide-1 receptor agonists decrease medical and surgical complications in morbidly obese patients undergoing primary TKA. J Bone Joint Surg Am. 2025, 107:348-55. 10.2106\/JBJS.24.00468","journal-title":"J Bone Joint Surg Am"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.sart.2024.10.001","article-title":"The impact of GLP-1 receptor agonists on postoperative outcomes following total shoulder arthroplasty","volume":"35(1)","author":"Choudhury A","year":"2025","unstructured":"Choudhury A, Van Boxtel M, Hanley J. The impact of GLP-1 receptor agonists on postoperative outcomes following total shoulder arthroplasty. Semin Arthroplasty: JSES. 2025, 35(1):94-9. 10.1053\/j.sart.2024.10.001","journal-title":"Semin Arthroplasty: JSES"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jse.2024.07.045","article-title":"Does use of glucagon-like peptide-1 agonists increase perioperative complications in patients undergoing shoulder arthroplasty?","volume":"34","author":"Elsabbagh Z","year":"2025","unstructured":"Elsabbagh Z, Haft M, Murali S, Best M, McFarland EG, Srikumaran U. Does use of glucagon-like peptide-1 agonists increase perioperative complications in patients undergoing shoulder arthroplasty?. J Shoulder Elbow Surg. 2025, 34:997-1006. 10.1016\/j.jse.2024.07.045","journal-title":"J Shoulder Elbow Surg"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jse.2024.09.012","article-title":"Glucagon-like peptide-1 receptor agonist use is associated with increased risk of perioperative complication and readmission following shoulder arthroplasty","volume":"34","author":"Lawand JJ","year":"2025","unstructured":"Lawand JJ, Tansey PJ, Ghali A, et al.. Glucagon-like peptide-1 receptor agonist use is associated with increased risk of perioperative complication and readmission following shoulder arthroplasty. J Shoulder Elbow Surg. 2025, 34:1152-7. 10.1016\/j.jse.2024.09.012","journal-title":"J Shoulder Elbow Surg"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jseint.2024.10.006","article-title":"Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: a promising new addition to preoperative optimization","volume":"9","author":"Seddio AE","year":"2025","unstructured":"Seddio AE, Wilhelm CV, Gouzoulis MJ, et al.. Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: a promising new addition to preoperative optimization. JSES Int. 2025, 9:735-40. 10.1016\/j.jseint.2024.10.006","journal-title":"JSES Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova M","year":"2025","unstructured":"Ukhanova M, Wozny JS, Truong CN, Ghosh L, Krause TM. Trends in glucagon-like peptide 1 receptor agonist prescribing patterns. Am J Manag Care. 2025, 31:e228-34. 10.37765\/ajmc.2025.89778","journal-title":"Am J Manag Care"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100162","article-title":"Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: a model-based meta-analysis of placebo-controlled trials","volume":"13","author":"Guo H","year":"2025","unstructured":"Guo H, Yang J, Huang J, et al.. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: a model-based meta-analysis of placebo-controlled trials. Obes Pillars. 2025, 13:100162. 10.1016\/j.obpill.2025.100162","journal-title":"Obes Pillars"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-019-0218-y","article-title":"The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis","volume":"16","author":"Que Q","year":"2019","unstructured":"Que Q, Guo X, Zhan L, et al.. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis. J Inflamm (Lond). 2019, 16:13. 10.1186\/s12950-019-0218-y","journal-title":"J Inflamm (Lond)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts\u00a0analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot C","year":"2022","unstructured":"Meurot C, Martin C, Sudre L, et al.. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts\u00a0analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022, 12:1567. 10.1038\/s41598-022-05323-7","journal-title":"Sci Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1177\/23259671241297157","article-title":"The impact of contemporary glucagon-like peptide-1 receptor agonists on the onset, severity, and conversion to arthroplasty in hip and knee osteoarthritis","volume":"13","author":"Porto JR","year":"2025","unstructured":"Porto JR, Lavu MS, Hecht CJ 2nd, Kaelber DC, Sculco PK, Heckmann ND, Kamath AF. The impact of contemporary glucagon-like peptide-1 receptor agonists on the onset, severity, and conversion to arthroplasty in hip and knee osteoarthritis. Orthop J Sports Med. 2025, 13:23259671241297157. 10.1177\/23259671241297157","journal-title":"Orthop J Sports Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-025-01486-8","article-title":"Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune\/autoinflammatory diseases","volume":"15","author":"Deng S","year":"2025","unstructured":"Deng S, Chen Z, Shi Y. Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune\/autoinflammatory diseases. Cell Biosci. 2025, 15:137. 10.1186\/s13578-025-01486-8","journal-title":"Cell Biosci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1333663","article-title":"Obesity and operative time in primary total joint arthroplasty","volume":"26","author":"Raphael IJ","year":"2013","unstructured":"Raphael IJ, Parmar M, Mehrganpour N, Sharkey PF, Parvizi J. Obesity and operative time in primary total joint arthroplasty. J Knee Surg. 2013, 26:95-9. 10.1055\/s-0033-1333663","journal-title":"J Knee Surg"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland IJ","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024, 26:16-27. 10.1111\/dom.15728","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/471723-systematic-review-evaluating-the-effects-of-glucagon-like-peptide-1-glp-1-receptor-agonist-use-on-the-postoperative-outcomes-of-patients-undergoing-arthroplasty-procedures","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T17:28:33Z","timestamp":1773595713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/471723-systematic-review-evaluating-the-effects-of-glucagon-like-peptide-1-glp-1-receptor-agonist-use-on-the-postoperative-outcomes-of-patients-undergoing-arthroplasty-procedures"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.105269","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,15]]}}}